Ranbaxy acquires U.S. rights to 13 Bristol-Myers Squibb dermatology brands

July 3, 2007

Bombay, India - Ranbaxy Laboratories Inc., a wholly owned subsidiary of Bombay-based Ranbaxy Laboratories Ltd., has acquired the U.S. rights to a group of 13 dermatology brands from Bristol-Myers Squibb Co. for $26 million, Domain-b.com reports.

Bombay, India - Ranbaxy Laboratories Inc., a wholly owned subsidiary of Bombay-based Ranbaxy Laboratories Ltd., has acquired the U.S. rights to a group of 13 dermatology brands from Bristol-Myers Squibb Co. for $26 million, Domain-b.com reports.

According to the Domain-b report, the acquisition enables the company to establish an immediate North American presence in disease segments such as dermatitis, psoriasis, scabies and anti-fungal, in addition to acne, where the company currently has a popular brand, Sotret Isotretinoin Capsules.

In addition, the acquisition creates a broader platform for the introduction of line extensions and additional brands, which will be marketed in the United States under the Ranbaxy Laboratories label.